Sale

Generic Injectables Market

Global Generic Injectables Market Share, Size, Forecast: By Product Type: Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Others; By Molecule Type; By Application; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Generic Injectables Market Outlook

The global generic injectables market size was valued at USD 114.47 billion in 2023, driven by the growing prevalence of cancer, coupled with rising demand for such drugs to assist patients undergoing chemotherapy, alleviating after-effects. The market is expected to grow at a CAGR of 13% during the forecast period 2024-2032 to attain a value of USD 343.87 billion by 2032.

 

Global Generic Injectables Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global generic injectables market is being driven by the growing prevalence of cancer, cardiovascular, and other diseases across the globe, coupled with rising demand for such drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain. The oncology segment, among other applications, dominates the industry, occupying a significant share. Among various distribution channels, hospitals account for the largest market share.

Region-wise, North America is the leading market, accounting for over a half of the total share. The growth of the global generic injectables market in the region can be attributed to the availability of advanced technology and enhanced healthcare infrastructure. On the other hand, the Asia Pacific is expected to be one of the emerging markets owing to the increased government expenditure in the healthcare sector in the region coupled with the presence of large population.

 

Market Segmentation

Generic injectables refer to the injectables that are bioequivalent of their branded counterparts and are not protected by drug patents. They are similar to original drugs and are safe and effective. They comprise of similar active ingredients, dosage, quality, and strength as their original counterparts, and, thus, their performance, intended use, quality, form, and route of administration are similar to that of their original counterparts.

 

Generic Injectables Market by Container

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on applications, the industry is divided into:

  • Oncology
  • Anaesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular
  • Others

On the basis of containers, the industry is categorised into:

  • Vials
  • Ampoules
  • Premix
  • Prefilled Syringes
  • Others

On the basis of distribution channel, the industry can be further segmented into:

  • Hospitals
  • Retail Pharmacy 

The report further analyses the regional markets like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Generic Injectables Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The global generic injectables market is driven by the growing prevalence of chronic, lethal, as well as lifestyle diseases across the globe, coupled with high costs associated with their treatment. These drugs are bioequivalent of and are used as an alternative means to brand-name medicines, providing similar pharmacological effects in the treatment of various diseases. With the rise in the number of patients, the use of generic injectables is growing as they save time and provide a quick relief by getting injected directly into the bloodstream.

Although the production of generic injectables is complex, their research and development investment is cheaper and takes less time. Unlike branded drug manufacturers, generic drug manufacturers need not invest heavily in the manufacturing and marketing of their products. The sudden increase in the overall healthcare costs has boosted the demand for these injectables. Further, the growing preference of generic oncology drugs for treating cancer patients is also contributing to the global generic injectables market. Rising geriatric population and growing demand for cost-effective treatment procedures, particularly in emerging regions are aiding the industry further.

Additionally, an increase in the shortage of drugs, especially in the United States, along with patent expiry of a number of useful and famous drugs, is, in turn, boosting the global generic injectables market. The growing research and development activities are aiding the market growth. Moreover, to satisfy the growing consumer demand, the leading players in the market are innovating and launching enhanced products. The development of the latest formulations by manufacturers is expected to have a positive effect on the global generic injectables market over the forecast period.  

 

Competitive Landscape

The report gives a detailed analysis of the following key players in the global generic injectables market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Fresenius Kabi 
  • Hikma Pharmaceuticals PLC
  • Sagent Pharmaceuticals, Inc.
  • Sanofi
  • Sandoz (Novartis)
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2023-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Molecule Type
  • Application
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Product Type
  • Monoclonal Antibodies
  • Immunoglobulin
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Vaccines
  • Chemotherapy Agents
  • Small Molecules Antibiotics
  • Others
Breakup by Molecule Type
  • Large Molecules
  • Small Molecules
Breakup by Application
  • Oncology
  • Infections Diseases
  • Diabetes
  • Blood Disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases
  • Others
Breakup by Route of Administration
  • Intramuscular
  • Intravenous
  • Subcutaneous
Breakup by Distribution Channel
  • Drug Store
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Abbott
  • B.D.
  • Novartis AG
  • Pfizer Inc.
  • Baxter
  • Gerresheimer AG
  • Germany
  • AstraZeneca
  • Terumo Medical Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Schott AG
  • Sanofi
  • Johnson & Johnson Private Limited
  • Mylan N.V.
  • West Pharmaceutical Services, Inc.
  • SHL Medical AG
  • Insulet Corporation
  • E3D Elcam
  • Drug Delivery Devices
  • Ypsomed AG
  • AbbVie Inc.
  • Novo Nordisk A/S
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Global Generics Injectable Market Overview 

    3.1    Global Generics Injectable Market Historical Value (2017-2023) 
    3.2    Global Generics Injectable Market Forecast Value (2024-2032)
4    Global Generics Injectable Market Landscape
    4.1        Global Generics Injectable Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Generics Injectable Product Landscape
        4.2.1    Analysis by Product Type
        4.2.2    Analysis by Applications
        4.2.3    Analysis by Distribution Channel
5    Global Generics Injectable Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Generics Injectable Market Segmentation
    6.1    Global Generics Injectable Market by Product Type
        6.1.1    Market Overview    
        6.1.2    Monoclonal Antibodies
        6.1.3    Immunoglobulin
        6.1.4    Cytokines
        6.1.5    Insulin
        6.1.6    Peptide Hormones
        6.1.7    Blood Factors
        6.1.8    Vaccines
        6.1.9    Chemotherapy Agents
        6.1.10    Small Molecules Antibiotics
        6.1.11    Others
    6.2    Global Generics Injectable Market by Molecule Type
        6.2.1    Market Overview 
        6.2.2    Large Molecules
        6.2.3    Small Molecules
    6.3    Global Generics Injectable Market by Application
        6.3.1    Market Overview
        6.3.2    Oncology
        6.3.3    Infections Diseases 
        6.3.4    Diabetes
        6.3.5    Blood Disorders
        6.3.6    Hormonal Disorders
        6.3.7    Musculoskeletal Disorders
        6.3.8    CNS Diseases
        6.3.9    Pain Management
        6.3.10    Cardiovascular Diseases
        6.3.11    Others
    6.4    Global Generics Injectable Market by Route of Administration
        6.4.1    Market Overview
        6.4.2    Intramuscular
        6.4.3    Intravenous
        6.4.4    Subcutaneous
    6.5    Global Generics Injectable Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Drug Store
        6.5.3    Hospital Pharmacies
        6.5.4    Online Pharmacies
        6.5.5    Retail Pharmacies
    6.6    Global Generics Injectable Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Generics Injectable Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Generics Injectable Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Generics Injectable Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Generics Injectable Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Generics Injectable Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Abbott
        17.1.1    Financial Analysis
        17.1.2     Product Portfolio
        17.1.3     Demographic Reach and Achievements
        17.1.4     Mergers and Acquisitions
        17.1.5     Certifications
    17.2     B.D.
        17.2.1    Financial Analysis
        17.2.2     Product Portfolio
        17.2.3     Demographic Reach and Achievements
        17.2.4     Mergers and Acquisitions
        17.2.5     Certifications
    17.3    Novartis AG
        17.3.1    Financial Analysis
        17.3.2     Product Portfolio
        17.3.3     Demographic Reach and Achievements
        17.3.4     Mergers and Acquisitions
        17.3.5     Certifications
    17.4    Pfizer Inc.
        17.4.1    Financial Analysis
        17.4.2     Product Portfolio
        17.4.3     Demographic Reach and Achievements
        17.4.4     Mergers and Acquisitions
        17.4.5     Certifications
    17.5    Baxter
        17.5.1    Financial Analysis
        17.5.2     Product Portfolio
        17.5.3     Demographic Reach and Achievements
        17.5.4     Mergers and Acquisitions
        17.5.5     Certifications
    17.6    Gerresheimer AG
        17.6.1    Financial Analysis
        17.6.2     Product Portfolio
        17.6.3     Demographic Reach and Achievements
        17.6.4     Mergers and Acquisitions
        17.6.5     Certifications
    17.7    Germany
        17.7.1    Financial Analysis
        17.7.2     Product Portfolio
        17.7.3     Demographic Reach and Achievements
        17.7.4     Mergers and Acquisitions
        17.7.5     Certifications
    17.8    AstraZeneca
        17.8.1    Financial Analysis
        17.8.2     Product Portfolio
        17.8.3     Demographic Reach and Achievements
        17.8.4     Mergers and Acquisitions
        17.8.5     Certifications
    17.9    Terumo Medical Corporation
        17.9.1    Financial Analysis
        17.9.2     Product Portfolio
        17.9.3     Demographic Reach and Achievements
        17.9.4     Mergers and Acquisitions
        17.9.5     Certifications
    17.10    Teva Pharmaceutical Industries Ltd.
        17.10.1    Financial Analysis
        17.10.2     Product Portfolio
        17.10.3     Demographic Reach and Achievements
        17.10.4     Mergers and Acquisitions
        17.10.5     Certifications
    17.11    Eli Lilly and Company
        17.11.1    Financial Analysis
        17.11.2     Product Portfolio
        17.11.3     Demographic Reach and Achievements
        17.11.4     Mergers and Acquisitions
        17.11.5     Certifications
    17.12    Schott AG
        17.12.1    Financial Analysis
        17.12.2     Product Portfolio
        17.12.3     Demographic Reach and Achievements
        17.12.4     Mergers and Acquisitions
        17.12.5     Certifications
    17.13    Sanofi
        17.13.1    Financial Analysis
        17.13.2     Product Portfolio
        17.13.3     Demographic Reach and Achievements
        17.13.4     Mergers and Acquisitions
        17.13.5     Certifications
    17.14    Johnson & Johnson Private Limited
        17.14.1    Financial Analysis
        17.14.2     Product Portfolio
        17.14.3     Demographic Reach and Achievements
        17.14.4     Mergers and Acquisitions
        17.14.5     Certifications
    17.15    Mylan N.V. 
        17.15.1    Financial Analysis
        17.15.2     Product Portfolio
        17.15.3     Demographic Reach and Achievements
        17.15.4     Mergers and Acquisitions
        17.15.5     Certifications
    17.16    West Pharmaceutical Services, Inc.
        17.16.1    Financial Analysis
        17.16.2     Product Portfolio
        17.16.3     Demographic Reach and Achievements
        17.16.4     Mergers and Acquisitions
        17.16.5     Certifications
    17.17    SHL Medical AG
        17.17.1    Financial Analysis
        17.17.2     Product Portfolio
        17.17.3     Demographic Reach and Achievements
        17.17.4     Mergers and Acquisitions
        17.17.5     Certifications
    17.18    Insulet Corporation
        17.18.1    Financial Analysis
        17.18.2     Product Portfolio
        17.18.3     Demographic Reach and Achievements
        17.18.4     Mergers and Acquisitions
        17.18.5     Certifications
    17.19    E3D Elcam
        17.19.1    Financial Analysis
        17.19.2     Product Portfolio
        17.19.3     Demographic Reach and Achievements
        17.19.4     Mergers and Acquisitions
        17.19.5     Certifications
    17.20    Drug Delivery Devices
        17.20.1    Financial Analysis
        17.20.2     Product Portfolio
        17.20.3     Demographic Reach and Achievements
        17.20.4     Mergers and Acquisitions
        17.20.5     Certifications
    17.21     Ypsomed AG
        17.21.1    Financial Analysis
        17.21.2     Product Portfolio
        17.21.3     Demographic Reach and Achievements
        17.21.4     Mergers and Acquisitions
        17.21.5     Certifications
    17.22    AbbVie Inc.
        17.22.1    Financial Analysis
        17.22.2     Product Portfolio
        17.22.3     Demographic Reach and Achievements
        17.22.4     Mergers and Acquisitions
        17.22.5     Certifications
    17.23    Novo Nordisk A/S
        17.23.1    Financial Analysis
        17.23.2     Product Portfolio
        17.23.3     Demographic Reach and Achievements
        17.23.4     Mergers and Acquisitions
        17.23.5     Certifications
18    Global Generics Injectable Market- Distribution Model (Additional Insight)
    18.1    Overview
    18.2    Potential Distributors
    18.3    Key Parameters for Distribution Partner Assessment
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Pricing Models and Strategies (Additional Insight)
    21.1    Overview
    21.2    Cost Model
        21.2.1    Manufacturing Cost Analysis
        21.2.2    Procurement Cost Analysis
        21.2.3    Clinical Trial Cost Factors
    21.3    Pricing Strategies
        21.3.1     Competitor Pricing Analysis
        21.3.2     Key Assessment of Product Attributes
        21.3.3     Pricing Benchmark

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for generic injectables attained a value of USD 114.47 billion.

The market is projected to grow at a CAGR of 13% during the forecast period of 2024-2032 to reach a value of USD 343.87 billion by 2032.

The major drivers of the industry include rising disposable incomes, increasing population, rising prevalence of chronic, lethal, and lifestyle diseases, and sudden increase in the overall healthcare costs.

The development of the latest formulations by manufacturers is expected to be a key trend guiding the growth of the industry.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market, with North America accounting for the largest market share.

The oncology segment is the dominant application sector of the product in the market. 

The major containers used in the industry can be divided into vials, ampoules, premix, and prefilled syringes, among others.

The hospitals segment accounts for the largest market share, among other distribution channels in the industry.

The leading players in the market are Fresenius Kabi, Hikma Pharmaceuticals PLC, Sagent Pharmaceuticals, Inc., Sanofi, and Sandoz (Novartis), among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER